<?xml version='1.0' encoding='utf-8'?>
<document id="29292668"><sentence text="Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients."><entity charOffset="24-33" id="DDI-PubMed.29292668.s1.e0" text="clozapine" /></sentence><sentence text="Objective Serious infections or inflammations have been associated with serum clozapine concentration increases and sometimes with clozapine toxicity"><entity charOffset="78-87" id="DDI-PubMed.29292668.s2.e0" text="clozapine" /><entity charOffset="131-140" id="DDI-PubMed.29292668.s2.e1" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.29292668.s2.e0" e2="DDI-PubMed.29292668.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29292668.s2.e0" e2="DDI-PubMed.29292668.s2.e1" /></sentence><sentence text=" Method These two cases describe Chinese patients (Case 1: a 57-year-old female nonsmoker with severe dermatitis and Case 2: a 47-year-old male nonsmoker with influenza and secondary infection)" /><sentence text=" Results In both cases, the Drug Interaction Probability Scale established the presence of a probable drug-drug interaction" /><sentence text=" In both cases, the clozapine and the total clozapine concentration-to-dose ratios followed a temporal pattern (normal-high-normal), consistent with an inhibition of clozapine metabolism during peak inflammation"><entity charOffset="20-29" id="DDI-PubMed.29292668.s5.e0" text="clozapine" /><entity charOffset="44-53" id="DDI-PubMed.29292668.s5.e1" text="clozapine" /><entity charOffset="166-175" id="DDI-PubMed.29292668.s5.e2" text="clozapine" /><pair ddi="false" e1="DDI-PubMed.29292668.s5.e0" e2="DDI-PubMed.29292668.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29292668.s5.e0" e2="DDI-PubMed.29292668.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29292668.s5.e0" e2="DDI-PubMed.29292668.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29292668.s5.e1" e2="DDI-PubMed.29292668.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29292668.s5.e1" e2="DDI-PubMed.29292668.s5.e2" /></sentence><sentence text=" In the first case, the total clozapine concentration-to-dose ratio (8 with no/low inflammation: median of 3"><entity charOffset="30-39" id="DDI-PubMed.29292668.s6.e0" text="clozapine" /></sentence><sentence text="10 and 2 at peak inflammation: median of 3" /><sentence text="90) provided a significant difference (P = 0" /><sentence text="044)" /><sentence text=" In the second patient, because of the smaller sample size and reduced statistical power (4 with no infection: a median of 1" /><sentence text="59 and 2 at peak infection: 3" /><sentence text="46), the increase did not reach significance (P = 0" /><sentence text="13)" /><sentence text=" In the first case, the median baseline clozapine concentration-to-dose ratio increased by a factor of 1"><entity charOffset="40-49" id="DDI-PubMed.29292668.s14.e0" text="clozapine" /></sentence><sentence text="45 from 2" /><sentence text="00 to a peak of 2" /><sentence text="89" /><sentence text=" To compensate for the inhibition of clozapine metabolism, the dose correction factor was 0"><entity charOffset="37-46" id="DDI-PubMed.29292668.s18.e0" text="clozapine" /></sentence><sentence text="69 (1/1" /><sentence text="45) or a decrease in dose of approximately one-third" /><sentence text=" In the second case, the median baseline clozapine concentration-to-dose ratio increased by a factor of 2"><entity charOffset="41-50" id="DDI-PubMed.29292668.s21.e0" text="clozapine" /></sentence><sentence text="56 from 1" /><sentence text="15 to a peak of 2" /><sentence text="94" /><sentence text=" Conclusion This provided a dose correction factor of 0" /><sentence text="40 (1/2" /><sentence text="56) or approximately half the dose, similar to published cases in Caucasians with serious respiratory infections" /><sentence text="" /></document>